Plasma and brain concentrations of oral therapeutic doses of methylphenidate and their impact on brain monoamine content in mice

Neuropharmacology

Volumn 57, Issue 7-8, 2009, Pages 687-693

  Balcioglu, Aygul ^a   Ren, Jia Qian ^a   McCarthy, Deirdre ^a   Spencer, Thomas J ^a   Biederman, Joseph ^a   Bhide, Pradeep G ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Dopamine; Frontal cortex; Methylphenidate; Ritalinic acid; Striatum

Indexed keywords

DOPAMINE; METHYLPHENIDATE; MONOAMINE; NORADRENALIN; RITALINIC ACID; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DETERMINATION; DRUG MECHANISM; FRONTAL CORTEX; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; RACEMIC MIXTURE; RAT; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ANIMALS; BIOGENIC MONOAMINES; BIOLOGICAL AVAILABILITY; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; CORPUS STRIATUM; FRONTAL LOBE; MALE; METHYLPHENIDATE; MICE; PLASMA; STEREOISOMERISM;

EID: 70350222339     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2009.07.025     Document Type: Article

References (45)

1. Andersen S.L., Arvanitogiannis A., Pliakas A.M., LeBlanc C., and Carlezon Jr. W.A. Altered responsiveness to cocaine in rats exposed to methylphenidate during development. Nat. Neurosci. 5 (2002) 13-14
2. Aoyama T., Kotaki H., Honda Y., and Nakagawa F. Kinetic analysis of enantiomers of threo-methylphenidate and its metabolite in two healthy subjects after oral administration as determined by a gas chromatographic-mass spectrometric method. J. Pharm. Sci. 79 (1990) 465-469
3. Aoyama T., Kotaki H., Sawada Y., and Iga T. Pharmacokinetics and pharmacodynamics of methylphenidate enantiomers in rats. Psychopharmacology (Berl) 127 (1996) 117-122
4. Augustyniak P.N., Kourrich S., Rezazadeh S.M., Stewart J., and Arvanitogiannis A. Differential behavioral and neurochemical effects of cocaine after early exposure to methylphenidate in an animal model of attention deficit hyperactivity disorder. Behav. Brain Res. 167 (2006) 379-382
5. Berridge C.W., Devilbiss D.M., Andrzejewski M.E., Arnsten A.F., Kelley A.E., Schmeichel B., Hamilton C., and Spencer R.C. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol. Psychiatry 60 (2006) 1111-1120
6. Biederman J., Wilens T., Mick E., Faraone S.V., Weber W., Curtis S., Thornell A., Pfister K., Jetton J.G., and Soriano J. Is ADHD a risk factor for psychoactive substance use disorders? Findings from a four-year prospective follow-up study. J. Am. Acad. Child. Adolesc. Psychiatry 36 (1997) 21-29
7. Biederman J., Wilens T.E., Mick E., Faraone S.V., and Spencer T. Does attention-deficit hyperactivity disorder impact the developmental course of drug and alcohol abuse and dependence?. Biol. Psychiatry 44 (1998) 269-273
8. Bolanos C.A., Barrot M., Berton O., Wallace-Black D., and Nestler E.J. Methylphenidate treatment during pre- and periadolescence alters behavioral responses to emotional stimuli at adulthood. Biol. Psychiatry 54 (2003) 1317-1329
9. Brandon C.L., Marinelli M., Baker L.K., and White F.J. Enhanced reactivity and vulnerability to cocaine following methylphenidate treatment in adolescent rats. Neuropsychopharmacology 25 (2001) 651-661
10. Brandon C.L., Marinelli M., and White F.J. Adolescent exposure to methylphenidate alters the activity of rat midbrain dopamine neurons. Biol. Psychiatry 54 (2003) 1338-1344
11. Carlezon Jr. W.A., Mague S.D., and Andersen S.L. Enduring behavioral effects of early exposure to methylphenidate in rats. Biol. Psychiatry 54 (2003) 1330-1337
12. Chase T.D., Carrey N., Brown R.E., and Wilkinson M. Methylphenidate differentially regulates c-fos and fosB expression in the developing rat striatum. Brain Res. Dev. Brain Res. 157 (2005) 181-191
13. Davids E., Zhang K., Tarazi F.I., and Baldessarini R.J. Stereoselective effects of methylphenidate on motor hyperactivity in juvenile rats induced by neonatal 6-hydroxydopamine lesioning. Psychopharmacology (Berl) 160 (2002) 92-98
14. Davids E., Zhang K., Tarazi F.I., and Baldessarini R.J. Animal models of attention-deficit hyperactivity disorder. Brain Res. Brain Res. Rev. 42 (2003) 1-21
15. Ding Y.S., Fowler J.S., Volkow N.D., Dewey S.L., Wang G.J., Logan J., Gatley S.J., and Pappas N. Chiral drugs: comparison of the pharmacokinetics of [11C]d-threo and L-threo-methylphenidate in the human and baboon brain. Psychopharmacology (Berl) 131 (1997) 71-78
16. Ding Y.S., Gatley S.J., Thanos P.K., Shea C., Garza V., Xu Y., Carter P., King P., Warner D., Taintor N.B., Park D.J., Pyatt B., Fowler J.S., and Volkow N.D. Brain kinetics of methylphenidate (Ritalin) enantiomers after oral administration. Synapse 53 (2004) 168-175
17. Gerasimov M.R., Franceschi M., Volkow N.D., Gifford A., Gatley S.J., Marsteller D., Molina P.E., and Dewey S.L. Comparison between intraperitoneal and oral methylphenidate administration: a microdialysis and locomotor activity study. J. Pharmacol. Exp. Ther. 295 (2000) 51-57
18. Klein-Schwartz W. Abuse and toxicity of methylphenidate. Curr. Opin. Pediatr. 14 (2002) 219-223
19. Kotaki H., Aoyama T., Nakazato F., Saitoh Y., and Nakagawa F. Interactions in tissue distribution between methylphenidate and pemoline. II. Effects of methylphenidate or its metabolite on plasma and tissue concentrations of pemoline in the rat. Chem. Pharm. Bull. (Tokyo) 36 (1988) 4560-4566
20. Kuczenski R., and Segal D.S. Locomotor effects of acute and repeated threshold doses of amphetamine and methylphenidate: relative roles of dopamine and norepinephrine. J. Pharmacol. Exp. Ther. 296 (2001) 876-883
21. Kuczenski R., and Segal D.S. Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine. J. Neurosci. 22 (2002) 7264-7271
22. Kuczenski R., and Segal D.S. Stimulant actions in rodents: implications for attention-deficit/hyperactivity disorder treatment and potential substance abuse. Biol. Psychiatry 57 (2005) 1391-1396
23. McCabe S.E., Teter C.J., Boyd C.J., and Guthrie S.K. Prevalence and correlates of illicit methylphenidate use among 8th, 10th, and 12th grade students in the United States, 2001. J. Adolesc. Health 35 (2004) 501-504
24. Meririnne E., Kankaanpaa A., and Seppala T. Rewarding properties of methylphenidate: sensitization by prior exposure to the drug and effects of dopamine D1- and D2-receptor antagonists. J. Pharmacol. Exp. Ther. 298 (2001) 539-550
25. Olfson M., Marcus S.C., Weissman M.M., and Jensen P.S. National trends in the use of psychotropic medications by children. J. Am. Acad. Child. Adolesc. Psychiatry 41 (2002) 514-521
26. Patrick K.S., Ellington K.R., and Breese G.R. Distribution of methylphenidate and p-hydroxymethylphenidate in rats. J. Pharmacol. Exp. Ther. 231 (1984) 61-65
27. Patrick K.S., and Markowitz J.S. Pharmacology of methylphenidate, amphetamine enantiomers and pemoline in attention-deficit hyperactivity disorder. Hum. Psychopharmacol. 12 (1997) 527-546
28. Randall S., and Hannigan J.H. In utero alcohol and postnatal methylphenidate: locomotion and dopamine receptors. Neurotoxicol. Teratol. 21 (1999) 587-593
29. Robbins T.W. ADHD and addiction. Nat. Med. 8 (2002) 24-25
30. Russell V.A., Sagvolden T., and Johansen E.B. Animal models of attention-deficit hyperactivity disorder. Behav. Brain Funct. 1 (2005) 9
31. Sagvolden T., Russell V.A., Aase H., Johansen E.B., and Farshbaf M. Rodent models of attention-deficit/hyperactivity disorder. Biol. Psychiatry 57 (2005) 1239-1247
32. Schweri M.M., Skolnick P., Rafferty M.F., Rice K.C., Janowsky A.J., and Paul S.M. [3H]Threo-(+/-)-methylphenidate binding to 3,4-dihydroxyphenylethylamine uptake sites in corpus striatum: correlation with the stimulant properties of ritalinic acid esters. J. Neurochem. 45 (1985) 1062-1070
33. Sprague R.L., and Sleator E.K. Methylphenidate in hyperkinetic children: differences in dose effects on learning and social behavior. Science 198 (1977) 1274-1276
34. Sulzer D., Sonders M.S., Poulsen N.W., and Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog. Neurobiol. 75 (2005) 406-433
35. Swanson J., Gupta S., Guinta D., Flynn D., Agler D., Lerner M., Williams L., Shoulson I., and Wigal S. Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Clin. Pharmacol. Ther. 66 (1999) 295-305
36. Swanson J.M., and Volkow N.D. Pharmacokinetic and pharmacodynamic properties of stimulants: implications for the design of new treatments for ADHD. Behav. Brain Res. 130 (2002) 73-78
37. Teter C.J., McCabe S.E., Boyd C.J., and Guthrie S.K. Illicit methylphenidate use in an undergraduate student sample: prevalence and risk factors. Pharmacotherapy 23 (2003) 609-617
38. Thai D.L., Yurasits L.N., Rudolph G.R., and Perel J.M. Comparative pharmacokinetics and tissue distribution of the d-enantiomers of para-substituted methylphenidate analogs. Drug Metab. Dispos. 27 (1999) 645-650
39. Thanos P.K., Michaelides M., Benveniste H., Wang G.J., and Volkow N.D. Effects of chronic oral methylphenidate on cocaine self-administration and striatal dopamine D2 receptors in rodents. Pharmacol. Biochem. Behav. 87 (2007) 426-433
40. Volkow N.D. Stimulant medications: how to minimize their reinforcing effects?. Am. J. Psychiatry 163 (2006) 359-361
41. Volkow N.D., Fowler J.S., Wang G., Ding Y., and Gatley S.J. Mechanism of action of methylphenidate: insights from PET imaging studies. J. Atten. Disord. 6 Suppl. 1 (2002) S31-S43
42. Volkow N.D., Wang G.J., Fowler J.S., Gatley S.J., Logan J., Ding Y.S., Hitzemann R., and Pappas N. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am. J. Psychiatry 155 (1998) 1325-1331
43. Wargin W., Patrick K., Kilts C., Gualtieri C.T., Ellington K., Mueller R.A., Kraemer G., and Breese G.R. Pharmacokinetics of methylphenidate in man, rat and monkey. J. Pharmacol. Exp. Ther. 226 (1983) 382-386
44. Wolf M.E., and Roth R.H. Autoreceptor regulation of dopamine synthesis. Ann. N.Y. Acad. Sci. 604 (1990) 323-343
45. Zuvekas S.H., Vitiello B., and Norquist G.S. Recent trends in stimulant medication use among U.S. children. Am. J. Psychiatry 163 (2006) 579-585